Methylation: When Whole Genome Sequencing is not Enough! | Illumina SciMon Video

2015年3月19日

While some cancers subtypes can be elucidated using whole exome sequencing, others show an epigenomic signature. Researchers explore the versatility of Illumina technology, across whole exome sequencing, whole genome sequencing and whole epigenome sequencing. Illumina’s EpiGnomeTM kit can eliminate PCR amplification steps, thereby reducing amplication biases, improving the feasibility of such research. Researchers have not only used sequencing to potentially identify the first therapeutic candidates for childhood brain tumors, but have also identified a methylator phenotype that can be used to distinguish between two tumor subtypes. For more information on applications of Illumina technology in the field of Epigenomics, please visit us at Illumina: Epigenomics http://www.illumina.com/applications/epigenetics.ilmn Products: HiSeq: http://www.illumina.com/systems/hiseq_2500_1500.ilmn Infinium 450K Methylation Array: http://www.illumina.com/products/methylation_450_beadchip_kits.ilmn EpigenomeTM Kit: http://www.illumina.com/products/truseq-dna-methylation.html Publication Links: PMID: 24553142 | Mack S.C., et al (2014): http://www.ncbi.nlm.nih.gov/pubmed/24553142 PMID: 24413733 | Brastianos P.K., et al (2014): http://www.ncbi.nlm.nih.gov/pubmed/24413733 Publication Research Reviews: http://www.illumina.com/science/publications/publications-review.ilmn The Science Mondays (SciMon) series is brought to you by Illumina http://www.illumina.com/ Illumina hosts Swati Kadam, Ph.D., Scientific Liaison, Scientific Affairs and Jacques Retief, Associate Director Scientific Affairs deliver 5 minutes of scientific enlightenment on the latest discoveries.

この記事を共有します